1-溴-4-(3-(2-甲氧基苄氧基)-丙基氧基)苯 | 642487-31-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-溴-4-(3-(2-甲氧基苄氧基)-丙基氧基)苯
• 英文名称: 1-bromo-4-(3-(2-methoxybenzyloxy)-propyloxy)benzene
• 英文别名: 1-bromo-4-[3-(2-methoxybenzyloxy)propoxy]benzene；1-bromo-4-[3-(2-methoxybenzyloxy)prop-1-yloxy]benzene；1-(3-(2-methoxybenzyloxy)propoxy)-4-bromobenzene；1-bromo-4-(3-(2-methoxybenzyloxy)propoxy)benzene；1-bromo-4-[3-[(2-methoxyphenyl)methoxy]propoxy]benzene
• CAS: 642487-31-8
• 化学式: C₁₇H₁₉BrO₃
• 分子量: 351.24
• InChiKey: BTHQFDICYSHLNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-溴-4-(3-(2-甲氧基苄氧基)-丙基氧基)苯 在 bis(tri-tert-butyl-phosphine) palladium⁽⁰⁾ 、 potassium tert-butylate 、 乙酰氯 作用下， 以 四氢呋喃 、 甲醇 、 甲苯 为溶剂， 反应 30.0h， 生成 (2R)-1-(4-[3-(2-methoxybenzyloxy)propoxy]phenyl)-2-(naphthalen-2-yloxymethyl)piperazine
  参考文献：
  名称：

  Discovery of novel non-peptidic ketopiperazine-based renin inhibitors

  摘要：

  Ketopiperazine 2 was designed from a previously published analog. Compound 2 was shown to be a novel, potent inhibitor of renin that, when administered orally, lowered blood pressure in a hypertensive double transgenic (human renin and angiotensinogen) mouse model. Compound 2 was further optimized to sub-nanomolar potency by designing an analog that addressed the S3 sub-pocket of the renin enzyme (16). (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.01.048
• 作为产物：
  描述：

  3-(2-甲氧基苄氧基)-1-碘丙烷 、 4-溴苯酚 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 18.0h， 以71%的产率得到1-溴-4-(3-(2-甲氧基苄氧基)-丙基氧基)苯
  参考文献：
  名称：

  [EN] PIPERAZINE DERIVATIVE RENIN INHIBITORS
  [FR] DERIVES DE PIPERAZINE AGISSANT COMME INHIBITEURS DE LA RENINE

  摘要：

  揭示了哌嗪衍生物，它们的制备以及作为肾素抑制剂的用途。化学式（I）：

  公开号：

  WO2004089915A1

文献信息

• Design and Preparation of Potent, Nonpeptidic, Bioavailable Renin Inhibitors
  作者：Olivier Bezençon、Daniel Bur、Thomas Weller、Sylvia Richard-Bildstein、Luboš Remeň、Thierry Sifferlen、Olivier Corminboeuf、Corinna Grisostomi、Christoph Boss、Lars Prade、Stéphane Delahaye、Alexander Treiber、Panja Strickner、Christoph Binkert、Patrick Hess、Beat Steiner、Walter Fischli

  DOI：10.1021/jm900022f

  日期：2009.6.25

  Starting from known piperidine renin inhibitors, a new series of 3,9-diazabicyclo[3.3.1]nonene derivatives was rationally designed and prepared. Optimization of the positions 3, 6, and 7 of the diazabicyclonene template led to potent renin inhibitors. The substituents attached at the positions 6 and 7 were essential for the binding affinity of these compounds for renin. The introduction of a substituent

  从已知的哌啶肾素抑制剂开始，合理设计和制备了一系列新的3,9-二氮杂双环[3.3.1]壬烯衍生物。优化二氮杂双环烯模板的位置3、6和7导致有效的肾素抑制剂。在6和7位上连接的取代基对于这些化合物对肾素的结合亲和力是必不可少的。引入在3位上连接的取代基不会改变结合亲和力，但可以调节ADME性质。我们的努力导致发现抑制肾素的化合物（+）- 26g，在缓冲液中的IC 50为0.20 nM，在血浆中的IC 50为19 nM。讨论了该化合物和其他类似化合物的药代动力学特性。化合物（+）- 26克 在大鼠中被很好地吸收，在体内10 mg / kg时有效。
• [EN] PIPERAZINE DERIVATIVE RENIN INHIBITORS<br/>[FR] DERIVES DE PIPERAZINE AGISSANT COMME INHIBITEURS DE LA RENINE
  申请人：WARNER LAMBERT CO

  公开号：WO2004089915A1

  公开（公告）日：2004-10-21

  Disclosed are piperazine derivatives, their manufacture and use as inhibitors of renin. Formula (I):

  揭示了哌嗪衍生物，它们的制备以及作为肾素抑制剂的用途。化学式（I）：
• [EN] TETRAHYDROPYRIDINE DERIVATIVES<br/>[FR] DERIVES DE TETRAHYDROPYRIDINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2005040120A1

  公开（公告）日：2005-05-06

  The invention relates to novel tetrahydropyridine derivatives and use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin. (I) wherein X and Y represent independently hydrogen, fluorine or a methyl group; X and Y do not represent both hydrogen at the same time or X and Y may together form a cyclopropyl ring; W represents a phenyl or a heteroaryl, the heteroaryl ring being a six-membered and non-fused ring, the phenyl ring and the heteroaryl are substituted with V in position 3 or 4; A and B independently represent -O-;-S-;-SO- or -SO2-; U represents aryl or heteroaryl; T represents -CONR1-;-(CH2)pOCO-; -(CH2)pN(R1)CO-; -(CH2)pN(R1)SO2-; -COO-; -(CH2)pOCONR1 - or -(CH2) pN(R2)CONR1-; R1 and R2 independently respresent hydrogen; lower alkyl; lower alkenyl; lower alkynil; cycloalkyl; aryl-lower alkyl, heteroaryl-lower alkyl or cycloalkyl - lower alkyl; Q represents lower alkylene or lower alkenylene; M represents hydrogen; cycloalkyl; aryl; heterocyclyl or heteroaryl:

  本发明涉及新型的四氢吡啶衍生物及其作为活性成分用于制备药物组合物中的应用。本发明还涉及相关方面，包括制备这些化合物的方法、含有一种或多种这些化合物的药物组合物，尤其是它们作为肾素抑制剂的应用。其中，X和Y分别独立地代表氢、氟或甲基；X和Y不同时代表氢，或者X和Y可以共同形成一个环丙基环；W代表苯基或杂芳基，杂芳基环是一个六元非融合环，苯基环和杂芳基在3或4位置被V取代；A和B独立地代表- O-；-S-；-SO-或-SO2-；U代表芳基或杂芳基；T代表-CONR1-；-(CH2)pOCO-；-(CH2)pN(R1)CO-；-(CH2)pN(R1)SO2-；-COO-；-(CH2)pOCONR1-或-(CH2)pN(R2)CONR1-；R1和R2分别独立地代表氢；低级烷基；低级烯基；低级炔基；环烷基；芳基低级烷基，杂芳基低级烷基或环烷基低级烷基；Q代表低级烷基或低级烯基；M代表氢；环烷基；芳基；杂环基或杂芳基：
• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSES ORGANIQUES
  申请人：SPEEDEL EXPERIMENTA AG

  公开号：WO2005037803A1

  公开（公告）日：2005-04-28

  Novel piperazine derivatives of the general formulae (I) and (II), with the substituent definitions as illustrated in detail in the description are described. The compounds are suitable especially as renin inhibitors and have high potency.

  描述了一种一般式(I)和(II)的新型哌嗪衍生物，其取代基定义如详细描述中所示。这些化合物特别适用于作为肾素抑制剂，并具有高效性。
• [EN] NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS<br/>[FR] NOUVEAUX DERIVES DE TETRAHYDROPYRIDINE EN TANT QU'INHIBITEURS DE RENINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2004002957A1

  公开（公告）日：2004-01-08

  The invention relates to novel tetrahydropyridine derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.

  该发明涉及新型四氢吡啶衍生物及相关化合物，以及它们作为药物组合物中活性成分的用途。该发明还涉及相关方面，包括制备这些化合物的过程、含有其中一个或多个这些化合物的药物组合物，特别是它们作为肾素抑制剂的用途。